Phase II Study of Erlotinib, an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

Trial Profile

Phase II Study of Erlotinib, an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Skin cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Mar 2018 Results (n=39) assessing efficacy and tolerability of erlotinib in patients with metastatic or recurrent cutaneous squamous cell carcinoma, were published in the Cancer.
    • 25 Sep 2017 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
    • 25 Sep 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top